TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04454203

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Perifemoral Injection of Local Anesthetic
Description: Infiltration of saline superomedially to the formal artery via perineural catheter that should NOT numb the nerves that contribute to tourniquet hypertension intraoperatively.
Study: NCT06709963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITBS
Description: We will use a coil called Cool-6000 A/P to conduct real and sham control. This coil will be placed on the scalp of older adults. The iTBS protocol will begin with a 2-s burst train (totally 30 pulses), repeating every 10 s. Each burst train will consist of 10 triplet pulses with an inter-burst interval of 0.16 s, thus the triplets fire at a rate of 5 Hz. ITBS parameters will include three continuous pulses at 50 Hz repeated at 5 Hz (2s on, 8s off) for a total of 600 pulses.~We will administer two rounds of iTBS per treatment day, with a 15-minute interval between the two sessions. In total, each participant will receive 1,200 stimuli during a single-session iTBS, totaling for 14 days. Each treatment session will last for about 30 minutes. Intermittent θ-burst stimulation intensity will be set at 70% of the resting motor threshold.
Study: NCT06398132

Intervention type: OTHER
Intervention: Usual Care
Description: Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
Study: NCT04549116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone-IBSA Injectable Solution
Description: Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Vaginal Gel with Applicator
Description: Crinone 8%, 90 mg, QD intravaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal gel with applicator
Description: Vaginal gel Placebo, once daily (QD) intravaginally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injectable solution
Description: Placebo injectable solution, BID SC Injection every 12 hours
Study: NCT06397937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHIFT team intervention
Description: The SHIFT team, comprising a community health worker (CHW), community social worker (CHW), and community nurse (CN) will visit the participant starting within 72 hours of hospital discharge and provide social service referrals related to food insecurity, housing, immigration, and employment, and assist with medical appointment preparation (CHW), deliver individualized counseling focused on coping skills, reducing caregiver strain, and the psychological distress associated with experiences of racism and SDOH (CSW), and address health literacy and review of treatment goals and medications (CN).
Study: NCT05058196

Intervention type: RADIATION
Group type: OTHER
Intervention: Whole breast radiotherapy
Description: Whole breast radiotherapy after surgery

Intervention type: RADIATION
Group type: OTHER
Intervention: Intra Operative Radiotherapy
Description: Intra Operative Radiotherapy
Study: NCT05994703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juul e-cigarette
Description: Juul use as often as the participant likes for 12 weeks.
Study: NCT05437666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and booklet
Description: The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)

Intervention type: OTHER
Group type: OTHER
Intervention: Booklet
Description: The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
Study: NCT06685692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: 125 mg twice daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: 250 mg twice daily for 28 days
Study: NCT06682806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT3789
Description: PRT3789 is administered as an intravenous infusion once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks
Study: NCT06684847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: subcutaneous placebo PH20 SC given by prefilled syringe
Study: NCT06430177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Su Jok
Description: Su Jok will be done

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Su Jok
Description: Su Jok will be done
Study: NCT05065424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Atropine and Fentanyl Premedication Arm
Description: Prior to the LISA procedure, the blinded bedside nurse will infuse IV Atropine, labelled as Atropine/Placebo, over 1 minute, followed by IV fentanyl, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After medication infusion, a primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Normal Saline Placebo Arm
Description: Prior to the Less Invasive Surfactant Administration procedure, the blinded bedside nurse will infuse IV Normal Saline, labelled as Atropine/Placebo, over 1 minute, followed by a second infusion of IV Normal Saline, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After Normal Saline infusion, primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record.
Study: NCT06691191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 mg
Description: After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg
Description: After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
Study: NCT04878263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hospitalization
Description: Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIL-EAS ic care pathway
Description: Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
Study: NCT06485843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OA-SYS
Description: OA-SYS is made of several types of cells obtained from fat tissue for the treatment of osteoarthritis.
Study: NCT06688006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: climate change short animation film
Description: For the short animated film, a scenario will be created that describes climate change, risk factors that threaten human health as a result of climate change, adverse health effects of climate change, adverse effects on maternal and foetal health, precautions to be taken to protect against and adapt to the adverse effects of climate change. In the short animation film, visual materials will be created that show the adverse effects of climate change by using developing technology. The created scenario will be prepared as a two-dimensional (2D) animation film with the support of Selçuk University SERATEM (Selçuk University Radio and Television Application Center). All lines, colours, decorations and characters used in the creation phase of the short animation film will be determined by the researchers. Once the drawing and animation phases are complete, the voice-over actors will be selected after a further review. The short animated film should be about 2-3 minutes long.
Study: NCT06626672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Intervention
Description: Access to a digital platform including weekly workout videos, live workouts, recipes, study summaries, and a consultation hour.
Study: NCT06709963

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ITBS
Description: We will use a coil called Cool-6000 A/P to conduct real and sham control. This coil will be placed on the scalp of older adults. The iTBS protocol will begin with a 2-s burst train (totally 30 pulses), repeating every 10 s. Each burst train will consist of 10 triplet pulses with an inter-burst interval of 0.16 s, thus the triplets fire at a rate of 5 Hz. ITBS parameters will include three continuous pulses at 50 Hz repeated at 5 Hz (2s on, 8s off) for a total of 600 pulses.~We will administer two rounds of iTBS per treatment day, with a 15-minute interval between the two sessions. In total, each participant will receive 1,200 stimuli during a single-session iTBS, totaling for 14 days. Each treatment session will last for about 30 minutes. Intermittent θ-burst stimulation intensity will be set at 70% of the resting motor threshold.
Study: NCT06768723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-up (specifically, Post-Activation Performance Enhancement)
Description: Assess which intervention delivered the best acute performance enhancements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm-up (specifically, Post-Activation Performance Enhancement)
Description: Assess which intervention delivered the best acute performance enhancements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-up (specifically, Post-Activation Performance Enhancement)
Description: Assess which intervention delivered the best acute performance enhancements.
Study: NCT04775459

Intervention type: DRUG
Intervention: Surfactant administration until 2020
Description: Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
Study: NCT06768723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-up (specifically, Post-Activation Performance Enhancement)
Description: Assess which intervention delivered the best acute performance enhancements.
Study: NCT06777784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Modern Nicotine Oral Product Cool Mint 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Modern Nicotine Oral Product Cool Mint 12 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Modern Nicotine Oral Product Cool Mint 12 mg Nicotine
Study: NCT04588857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
Study: NCT05804825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Argument inoculation messages
Description: Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple forewarning message
Description: Participants will be presented with a simple forewarning message.
Study: NCT06311266

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic endoscopic neurosurgical intervention
Description: Robotic guidance device for intraoperative trajectory alignment in endoscopic neurosurgical procedures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic endoscopic neurosurgical intervention
Description: Robotic guidance device for intraoperative trajectory alignment in endoscopic neurosurgical procedures
Study: NCT04775459

Intervention type: DRUG
Intervention: Surfactant administration since 2021
Description: Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
Study: NCT06623890

Intervention type: DRUG
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm.
Study: NCT06622590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
Study: NCT06777784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Modern Nicotine Oral Product Cool Mint 12 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Modern Nicotine Oral Product Cool Mint 12 mg Nicotine
Study: NCT05067023

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: All participants will undergo 1 DCE-MRI scan.
Study: NCT06622590

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
Study: NCT04962139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON101 Cream
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: ON101 Cream Placebo
Study: NCT05694364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an antimetabolite given prior to lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an antimetabolite given prior to lymphodepletion.
Study: NCT06225336

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AUR-201
Description: Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
Study: NCT06162702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
Study: NCT02911961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
Study: NCT05694364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3007
Description: PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3007
Description: PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
Study: NCT05394636

Intervention type: OTHER
Intervention: None, pure observational study
Description: None, pure observational study